Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
236results about How to "Increased energy expenditure" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Mobile computing weight, diet, nutrition, and exercise tracking system with enhanced feedback and data acquisition functionality
InactiveUS8690578B1Good for weight lossRelieve painPhysical therapies and activitiesData processing applicationsNutritionSynthetic data
An illustrative mobile computing device executing weight, nutrition, health, behavior and exercise application software serves as a simulated combination personal trainer and dietician / nutritionist for the user using comprehensive databases storing personalized health, nutrition and exercise information. A mobile computing device, such as a smartphone, executing such software monitors, tracks and / or adjusts caloric intake, energy expenditure taking into account nutritional information and behavioral factors. The mobile computing device receives food consumption, exercise-related, behavior and other input using speech input and the device's GPS subsystem to ease data entry burden on users and to promote continued long-term usage. The system rewards user goal achievement in an automatic, seamless manner, through, for example, downloading music, books, or other media. In illustrative implementations, the system assists users to make healthy food and exercise choices by using a comprehensive color code system to identify good choices, bad choices and those in between.
Owner:SMARTEN LLC
Electric modulation of sympathetic nervous system
InactiveUS7239912B2Increase energy expenditureReduce food intakeInternal electrodesExternal electrodesNervous systemAdrenal tissue
A method for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.
Owner:ADVANCED NEUROMODULATION SYST INC
Dynamic nerve stimulation for treatment of disorders
ActiveUS7689276B2Increased energy expenditureReducing food intakeSpinal electrodesDiseasePhysical therapy
A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. Dynamic stimulation through ramped cycling of electrical stimulation, stimulation frequency alteration, and / or duty cycle variance can produce therapeutic benefits.
Owner:ADVANCED NEUROMODULATION SYST INC
Pharmaceutical formulations of potassium ATP channel openers and uses thereof
InactiveUS20060051418A1Enhanced drug releaseReduces food uptakeBiocideOrganic active ingredientsPotassium channel openerPotassium
Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering KATP channel openers with other drugs to treat diseases of humans and animals.
Owner:ESSENTIALIS INC
Method and system for modulating energy expenditure and neurotrophic factors
InactiveUS20080046012A1Symptoms improvedImprove performanceElectrotherapyImplantable ElectrodesRegimen
A method system for modulating the energy expenditure and / or the expressed brain-derived neurotrophic factor (BDNF) in the brain of an individual is performed by a system that includes a control device that generates a stimulation pattern from a predetermined set of stimulation parameters, and that converts the stimulation pattern into a stimulation signal. A stimulation signal delivery mechanism, configured for implantation into a selected part of the brain, receives the stimulation signal from the control device and delivers the signal to the selected part of the brain. The stimulation signal may be an electrical signal delivered by a brain-implantable electrode, or a chemical signal in the form of a drug dosage regimen delivered by an implantable micropump under the control of the control device. Modulation of the energy expenditure and / or BDNF is achieved by the stimulation of the hypothalamus, either directly or indirectly, by the stimulation signal.
Owner:RGT UNIV OF CALIFORNIA
Combination of bupropion and a second compound for affecting weight loss
InactiveUS20060058293A1Increased energy expenditureAppetite suppressantBiocideNervous disorderMelanocortin 3 receptorMC4 Receptor
Disclosed are compositions for affecting weight loss comprising bupropion and a second compound, where the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions, antagonizes cannabinoid receptor activity, or is useful in the treatment of bipolar disorders. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a combination of bupropion and a compound that enhances α-MSH activity, antagonizes cannabinoid receptor activity, or is useful in the treatment of bipolar disorders.
Owner:OREXIGEN THERAPEUTICS INC
Compositions for affecting weight loss
InactiveUS20070275970A1Appetite suppressantReduce weightBiocideMetabolism disorderOpioid antagonistMelanocortin 3 receptor
Owner:OREXIGEN THERAPEUTICS INC
Methods and devices for activating brown apidose tissue using electrical energy
ActiveUS20110270360A1Increased energy expenditureImplantable neurostimulatorsSubcutaneous electrodesElectricityMicrochiroptera
Methods and devices are provided for activating brown adipose tissue (BAT). Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss. In one embodiment, a medical device is provided that activates BAT by electrically stimulating nerves that activate the BAT and / or electrically stimulating brown adipocytes directly, thereby increasing thermogenesis in the BAT and inducing weight loss through energy expenditure.
Owner:THE GENERAL HOSPITAL CORP +1
Splanchnic nerve stimulation for treatment of obesity
InactiveUS7551964B2Increased energy expenditureReducing food intakeElectrotherapyArtificial respirationDiseaseSplanchnic nerve stimulation
A method for the treatment of obesity or other disorders by electrical activation or inhibition of the sympathetic nervous system is disclosed. This activation or inhibition can be accomplished by stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an electrode. This nerve activation can result in reduced food intake and increased energy expenditure.
Owner:ADVANCED NEUROMODULATION SYST INC
New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabidivarin
InactiveUS20100317729A1Enhanced treatment optionGood for weight lossBiocideNervous disorderCannabinoidPharmaceutical formulation
The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and / or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB1 and / or CB2 receptor. Preferably both the inverse agonist of the CB1 and / or CB2 receptor and the neutral antagonist of the CB1 and / or CB2 receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).
Owner:GW PHARMA LTD
Systems, methods and devices for promoting thermogenesis
ActiveUS20090048538A1Economy of scale in manufacturingPromoting thermogenesisElectrotherapyPerson identificationEngineeringBody posture
Systems, methods and devices to measure and potentially promote thermogenesis, preferably non-exercise activity thermogenesis are disclosed. In the various embodiments, the present invention may rely on one or more sensors that detect a subject's body posture and / or activity. Feedback regarding the subject's posture and / or activity (relative to preferred postures and / or activity levels) may preferably be provided after the data is retrieved and analyzed. A power interlock may also be used to control delivery of electrical energy based on a subject's posture and / or activity level.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Acylated glucagon analogues
InactiveUS20120178670A1Avoid weight gainGood for weight lossPeptide/protein ingredientsAntipyreticDiabetes mellitusWeight gain prevention
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Use for cannabinoids
InactiveUS20130245110A1High activityLess degree of activityBiocideOrganic chemistryDyslipidemiaCholesterol
The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease.
Owner:GW PHARMA LTD
Mobile computing weight, diet, nutrition, and exercise management system with enhanced feedback and goal achieving functionality
InactiveUS20140214446A1To promote metabolismIncrease satiety, prepackaged, low and zero calorie foodsPhysical therapies and activitiesData processing applicationsNutritionSynthetic data
An illustrative mobile computing device executing weight, nutrition, health, behavior and exercise application software serves as a simulated combination personal trainer and dietician / nutritionist for the user using comprehensive databases storing personalized health, nutrition and exercise information. A mobile computing device, such as a smartphone, executing such software monitors, tracks and / or adjusts caloric intake, energy expenditure taking into account nutritional information and behavioral factors. The mobile computing device receives food consumption, exercise-related, behavior and other input using speech input and the device's GPS subsystem to ease data entry burden on users and to promote continued long-term usage. The system rewards user goal achievement in an automatic, seamless manner, through, for example, downloading music, books, or other media. In illustrative implementations, the system assists users to make healthy food and exercise choices by using a comprehensive color code system to identify good choices, bad choices and those in between.
Owner:SMARTEN LLC
Compositions for affecting weight loss
InactiveUS20070270450A1Appetite suppressantReduce weightBiocideMetabolism disorderOpioid antagonistMelanocortin 3 receptor
Owner:OREXIGEN THERAPEUTICS INC
Compositions for affecting weight loss
ActiveUS20060142290A1Appetite suppressantReduce weightBiocideMetabolism disorderOpioid antagonistMelanocortin 3 receptor
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.
Owner:OREXIGEN THERAPEUTICS INC
Modified FGF-23 Polypeptides and Their Uses
InactiveUS20110015345A1Improve propertiesExtended half-lifePeptide/protein ingredientsPeptide preparation methodsChemistry
Owner:AMBRX
Methods and devices for activating brown adipose tissue with cooling
ActiveUS20150119849A1Increase energy expenditureHigh densityMedical devicesPressure infusionBrown adipose tissueCold sensitive
Methods and devices are provided for activating brown adipose tissue (BAT) with cooling. Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss and / or improved metabolic function. In one embodiment, a medical device is provided that activates BAT by cooling tissue having a high density of cold sensitive thermoreceptors and / or by cooling BAT depots directly, thereby increasing thermogenesis in the BAT and inducing weight loss and / or improved metabolic function through energy expenditure.
Owner:THE GENERAL HOSPITAL CORP +1
Methods and devices for activating brown adipose tissue with targeted substance delivery
ActiveUS9610429B2Increased energy expenditureElectrocardiographyMedical devicesBrown adipose cellMicrochiroptera
Methods and devices are provided for activating brown adipose tissue with targeted substance delivery. Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss and / or improved metabolic function. In one embodiment, a chemical configured to stimulate nerves that activate the BAT and / or to stimulate brown adipocytes directly can be delivered to a patient, thereby increasing thermogenesis in the BAT and inducing weight loss and / or improved metabolic function through energy expenditure. The chemical can be delivered to the patient locally and / or systemically to stimulate the nerves and / or the brown adipocytes.
Owner:THE GENERAL HOSPITAL CORP +1
Glucagon analogues
ActiveUS20140080757A1Avoid weight gainGood for weight lossBacteriaPeptide/protein ingredientsProviding materialObesity
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Dynamic nerve stimulation in combination with other eating disorder treatment modalities
ActiveUS20100106207A1Provide central nervous system satietyIncreased energy expenditureOrganic active ingredientsElectrotherapyDiseaseWeight-loss drugs
A method for treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and / or administering a weight loss drug.
Owner:ADVANCED NEUROMODULATION SYST INC
Use of akkermansia for treating metabolic disorders
PendingUS20150306152A1Increased energy expenditureIncrease satietyBiocideNervous disorderPharmaceutical drugPharmacology
The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.
Owner:UNIVERSITE CATHOLIQUE DE LOUVAIN +1
Modification of Feeding Behaviour
InactiveUS20080064636A1Reduce weightIncreased energy expenditurePeptide/protein ingredientsMetabolism disorderEnergy expenditureBiology
The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and / or increase energy expenditure.
Owner:IMPERIAL INNOVATIONS LTD
Acylated glucagon analogues
ActiveUS20150111826A1Avoid weight gainGood for weight lossOrganic active ingredientsPeptide/protein ingredientsDiseaseReceptor
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Glucagon analogues
InactiveUS20130157935A1Effect on cholesterol levelAvoid weight gainPeptide/protein ingredientsMetabolism disorderWeight gain preventionProviding material
The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Splanchnic Nerve Stimulation for Treatment of Obesity
InactiveUS20100234907A1Increased energy expenditureReducing food intakeSpinal electrodesArtificial respirationSplanchnic nerve stimulationDisease
Owner:DOBAK III JOHN D
Glucagon analogues
ActiveUS20150111817A1Avoid weight gainGood for weight lossNervous disorderBacteriaProviding materialObesity
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Splanchnic nerve stimulation for treatment of obesity
InactiveUS20090259279A1Provide central nervous system satietyIncreased energy expenditureSpinal electrodesArtificial respirationDiseaseSplanchnic nerve stimulation
A method for the treatment of obesity or other disorders by electrical activation or inhibition of the sympathetic nervous system is disclosed. This activation or inhibition can be accomplished by stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an electrode. This nerve activation can result in reduced food intake and increased energy expenditure.
Owner:DOBAK III JOHN D
Methods for increasing cellular energy expenditure
InactiveUS20080031968A1Increased cellular energy expenditureImprove metabolic controlCompound screeningApoptosis detectionG protein-coupled receptorAgonist
The present invention is directed to methods of treating a human for a variety of conditions by administering an agonist of the G protein coupled receptor TGR5. In addition, the invention includes methods for determining whether a test compound is likely to be effective in treating one of these conditions by assaying it for its ability to raise intracellular iodothyronine deiodinase levels or for its ability to bind to and activate TGR5.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +1
Glucagon analogues
ActiveUS9180169B2Avoid weight gainGood for weight lossPeptide/protein ingredientsMetabolism disorderProviding materialObesity
Owner:ZEALAND PHARM AS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com